Endocrine Hypertension: The Urgent Need for Greater Global Awareness.

TouchREVIEWS in endocrinology Pub Date : 2023-11-01 Epub Date: 2023-10-20 DOI:10.17925/EE.2023.19.2.11
Cornelius J Fernandez, Lakshmi Nagendra, Mohammed Alkhalifah, Joseph M Pappachan
{"title":"Endocrine Hypertension: The Urgent Need for Greater Global Awareness.","authors":"Cornelius J Fernandez, Lakshmi Nagendra, Mohammed Alkhalifah, Joseph M Pappachan","doi":"10.17925/EE.2023.19.2.11","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertension affects about 1.28 billion adults globally, and significantly increases the risk of chronic morbidity and mortality among sufferers. About 15% of these individuals have secondary hypertension, the majority of whom have dysfunction of one or more endocrine systems as the cause of hypertension. Although adrenal disorders are often identified as the cause of endocrine hypertension, extra-adrenal disease and pituitary disorders also can cause the disease. Timely diagnosis is of paramount importance, because of the potential for a surgical cure or optimal disease control with pharmacotherapy to prevent hypertensive complications. Even with its relatively high prevalence compared with many other chronic illnesses, the diagnosis of endocrine hypertension is often delayed or never made because of poor awareness about the disease among physicians. This review attempts to provide an overview of the disease, with some practical aspects of diagnosis and management of a few of the important disorders causing endocrine hypertension.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":"19 2","pages":"31-41"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769474/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TouchREVIEWS in endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2023.19.2.11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/20 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Hypertension affects about 1.28 billion adults globally, and significantly increases the risk of chronic morbidity and mortality among sufferers. About 15% of these individuals have secondary hypertension, the majority of whom have dysfunction of one or more endocrine systems as the cause of hypertension. Although adrenal disorders are often identified as the cause of endocrine hypertension, extra-adrenal disease and pituitary disorders also can cause the disease. Timely diagnosis is of paramount importance, because of the potential for a surgical cure or optimal disease control with pharmacotherapy to prevent hypertensive complications. Even with its relatively high prevalence compared with many other chronic illnesses, the diagnosis of endocrine hypertension is often delayed or never made because of poor awareness about the disease among physicians. This review attempts to provide an overview of the disease, with some practical aspects of diagnosis and management of a few of the important disorders causing endocrine hypertension.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
内分泌高血压:提高全球认识的迫切需要。
高血压影响着全球约 12.8 亿成年人,大大增加了患者的慢性发病率和死亡率。这些人中约有 15%患有继发性高血压,其中大多数人的高血压是由一种或多种内分泌系统功能失调引起的。虽然肾上腺疾病通常被认为是内分泌性高血压的病因,但肾上腺外疾病和垂体疾病也可导致该病。及时诊断至关重要,因为有可能通过手术治愈或通过药物治疗达到最佳的疾病控制效果,从而预防高血压并发症。尽管内分泌性高血压的发病率比许多其他慢性疾病都要高,但由于医生对该病的认识不足,内分泌性高血压的诊断往往被延误或从未确诊。本综述试图对该疾病进行概述,并对引起内分泌性高血压的几种重要疾病的诊断和管理提供一些实用的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
期刊最新文献
Amyloid Goiter: A Peruvian Case Series. Clinical and Biochemical Profiles of Hospitalized Patients with Hypercalcaemia from a Tertiary Care Centre in North India. Dry Eye in Diabetes: The Indian Diabetic and Endocrine Eye Diseases (INDEED) Review. Efficacy and Safety of Novel Twincretin Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, as an Anti-obesity Medicine in Individuals Without Diabetes: A Systematic Review and Meta-analysis. Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes: A Deadly Synergy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1